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Synopsis
Many attempts have been made to utilize interferons for the treatment or prevention of
infectious diseases because of their natural antiviral and immunomodulating activity. This article
explains the rationale for development of interferons as therapeutic agents and describes commercial
products available today. It also provides a summary of studies that have been performed with
interferons for use as exogenous biological response modifiers in viral infections. Overall the best data
exist for treatment of viral hepatitis B and C where interferons are a cornerstone of therapy. While
infections with human papillomavirus and common cold viruses sometimes respond favorably to
interferons, their outcomes are far from ideal. Finally, the role of interferons as vaccine adjuvants is still
being explored, but could be promising.
Introduction
Interferons (IFNs) are attractive biological response modifiers for use as therapeutic agents in
infectious diseases because they have both antiviral and immunomodulatory activity. Their name even
comes from the fact that they can “interfere” with viral replication.[1] IFN-α (“leukocyte interferon”)
and IFN-β (“fibroblast interferon”) are released by human cells infected with certain viruses while IFN-γ
(“immune interferon”) is produced by natural killer cells (T-cell lymphocytes) in response to antigen
exposure. These cytokines then act on uninfected host tissue cells to induce a state of relative
resistance to viral infections.[2] The agents bind to specific cell-surface receptors that initiate a series of
intracellular events: induction of certain enzymes, inhibition of cell proliferation, and enhancement of
immune activities including increased phagocytosis by macrophages and augmentation of specific
cytotoxicity by T lymphocytes.[3] Further details on endogenous interferon action and an explanation of
their activity as biological response modifiers, including in bacterial infections, can be found elsewhere
in this issue.[4]
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Even though interferons role against viruses is most prominent, they can also be induced by,
and active against, rickettsia, mycobacteria and several protozoa.[1] Therapeutically, however, their use
has generally been limited to treatment or prevention of viral infections. Although their potent antiviral
activity is promising - inhibiting viral replication in vitro at concentrations as low as pg/mL – the
development of interferons as clinically useful drugs has been largely disappointing. This can be
attributed partly to their short half-life in vivo and extensive side effects. In fact, many symptoms of
viral infections such as influenza can be blamed on endogenous interferon release. The adverse effects
prevalent at therapeutic doses include fever, myalgia, and headache dubbed “flu-like symptoms”, along
with bone marrow suppression leading to leukocytopenia and thrombocytopenia, plus central nervous
system manifestations including depression.[1]
Interferons have been studied for the treatment or prevention of herpes zoster, herpes simplex,
and cytomegalovirus infections, but the successful development of acyclovir and ganciclovir gave
clinicians safer and more effective alternatives for dealing with these viruses.[5, 6] IFNs can also be used
in the treatment of multiple sclerosis and certain cancers, but this article will review the therapeutic
applications of interferons for infectious diseases, focusing on viral infections.
Interferons and IFN-inducers available commercially
Interferons are not absorbed orally because of their large amino-acid sequence which is
susceptible to the proteoltyic enzymes in the digestive tract. However, IFN-α is readily absorbed after
both intramuscular and subcutaneous injection.[7] This rapid absorption combined with a short half-life
means that frequent injections are needed to maintain adequate concentrations in the body. Both
commercially available alpha interferon products in the U.S. have now been chemically attached to
polyethylene glycol (PEG) to enhance their half-life and make once-weekly dosing possible. This not only

3

makes administration easier, but it also reduces side effects by having a predictably lower peak
concentration of the exogenous cytokine.
Both pegylated INFα-2a (Pegasys) and IFNα-2b (PegIntron) are obtained from E. coli by
recombinant methods. They consist of naturally occurring small proteins with molecular weights of
15,000-27,600 daltons.[3] Each is considered a first-line option for the treatment of chronic hepatitis C
virus infection in combination with ribavirin. More details on this use and others will be described later
in the paper. Along with the list of additional FDA-approved indications in table 1, IFN-α was shown to
be an effective treatment for the symptoms of an aggressive case of chronic active Epstein-Barr virus,
but it did eliminate infection entirely.[8] Therefore additional studies would need to be performed
before recommendation for this use.
Human leukocyte derived IFNα-n3 (Alferon N) injection contains a spectrum of alpha interferons
and is only approved for the treatment of refractory or recurring condylomata acuminata in adult
patients. A low dose oral version is in development for use in the treatment and prevention of
influenza.[9] Both versions have been studied against HIV-1 infection, but with little success.[10, 11]
Interferon alfacon-1 (Infergen) is considered the synthetic “consensus interferon” because it contains a
non-natural sequence of IFN-α amino acids all chosen for the highest activity against viral hepatitis. To
date, no pegylated formulation of this product has been brought to market. All the alpha interferons
include a black box warning in their prescribing information about how their use “may cause or
aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic and infectious disorders.
Patients should be monitored closely with periodic clinical and laboratory evaluations. Therapy should
be withdrawn in patients with persistently severe or worsening signs and symptoms related to side
effects. In many, but not all cases, these resolve after stopping therapy.”[12, 13]
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Interferon-β-1a (Avonex or Rebif) and IFN-β-1b (Betaseron) are recombinant proteins with 166and 165-amino acids respectively. These beta interferons have antiviral and immunomodulatory
properties too, but their use at this time is limited to treatment of multiple sclerosis, not infections.
Interferon-γ-1b (ACTIMMUNE) injection is used regularly for the prevention of infections in patients with
chronic granulomatous disease along with antibacterials and antifungals.[14] Its mechanism of action
for this purpose is not entirely known, but long-term studies show a definite benefit.[15] Gamma
interferon can also be used as a salvage therapy for mycobacterial infections, but it is not routinely
utilized for treatment of this or other infections.[16]
Topical imiquimod 5% (Aldara) and 3.75% (Zyclara) creams do not have inherent antiviral activity
alone but instead induce IFN-α, -β and -γ plus tumor necrosis factor (TNF)-α through toll-like receptors.
Local application to external genital and perianal warts results in an immunomodulatory response that
stimulates cytokines which have antiviral action and cause a reduction in both viral load and wart
size.[3]
Use of interferons for hepatitis viruses
Chronic infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) affects over 400 million
people worldwide.[17-19] Chronic viral hepatitis is a leading cause of cirrhosis, liver transplantation and
hepatocellular carcinoma. With the development of a vaccination series for hepatitis B in the mid1980’s, along with increased public education and awareness, acute infection rates of both HBV and HCV
in the U.S. have declined steadily.[19]
Hepatitis B virus is a double-stranded DNA virus whereas HCV is a single-stranded RNA virus,
both of which are capable of significant morbidity and mortality in chronic infection. The exact
mechanisms of hepatic injury from HBV and HCV infection are not completely understood. Because
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asymptomatic carriers with normal liver transaminases exist, it is likely multiple immune-mediated
mechanisms result in hepatocyte damage as opposed to the virus itself being directly cytotoxic.
Following acute viral infection, the innate immune response initiates formation of natural killer
(NK) cells, followed by virus-specific CD4+ T cells, and CD8+ cytotoxic T lymphocytes. Natural killer cells
stimulate production of IFN-α/β and promote cellular clearance of viral proteins through disruption of
the replication process. Following successful clearance, either spontaneously or by treatment with IFN,
peripheral cytotoxic T lymphocytes and CD4+ T cell response persists.[20] Chronic infection is likely a
result of failed innate and adaptive immunity. Specifically, chronic infection with HCV has been
associated with impaired T cell and NK cell response.[21-24] Genetic factors also likely influence
progression of disease and predisposition to adverse effects.[25] Though an abundance of research has
investigated the immune response in relation to chronic viral hepatitis, many areas of uncertainty still
exist.
Standard alpha interferon, the first approved IFN for viral hepatitis, lacked several desirable
pharmacokinetic properties. The addition of PEG created an IFN that has a slower rate of absorption,
reduced elimination and a longer half-life, necessitating less frequent dosing and fewer adverse effects.
Furthermore, the PEG moiety results in reduced immunogenicity and sterically hinders the antigenic
binding site.[26, 27] Although pegylated IFN has replaced standard IFN-α in treatment of chronic HBV
and HCV, as many as 40 to 50% of patients still fail to respond to treatment. Successful response
depends on many factors including but not limited to viral genotype, viral load and degree of liver
fibrosis.[25]
Chronic hepatitis B and C are treated similarly with peginterferon (peg-IFN); however, only
peginterferon α -2a is FDA approved in the U.S. for treatment of HBV. Both peg-IFN products are
administered as subcutaneous injections once weekly for durations up to 48 weeks, dependent upon
6

viral genotype and early viral response for treatment of HCV. Peginterferon α -2b is dosed based on
body weight (1.5 µg/kg once weekly) whereas peginterferon α -2a is a fixed dose (180 µg/week).
Ribavirin is used in combination with peg-IFN for treatment of HCV. The exact mechanism of action of
ribavirin as an adjunctive antiviral agent in HCV is not completely understood.[12, 13] Some studies have
proposed ribavirin to act as an interferon stimulated gene inducer to improve second phase viral
decline.[28] Protease inhibitors (boceprevir and telaprevir) are recently approved adjunctive oral agents
for the treatment of chronic HCV with peg-IFN and ribavirin. To date, all studies of protease inhibitors
have been conducted in patients with HCV genotype 1, and have shown an increase in sustained
virologic response (SVR) rates particularly for patients previously unresponsive to IFN therapy.[29-35].
The use of IFN for the treatment of chronic HBV and HCV has represented a mainstay of
treatment for several decades. The specific mechanisms behind the antiviral effects of IFN for hepatitis
are complex. Interferon stimulated genes are induced by IFN and disrupt viral replication. Hundreds of
IFN-stimulated genes are thought to exist. Viperin, ISG20 and protein-kinase R (PKR) are just a few of the
most commonly cited. It is also highly possible that interferon stimulated genes work synergistically to
produce antiviral activities.[36, 37] A lack of PKR can lead to an environment conducive to HCV
replication, though it may not be a good predictor of exogenous IFN response. The study of interferon
stimulated genes and their role in determining who responds to IFN therapy has been evaluated in
several studies.[25, 36, 38] Additional studies of interferon stimulated gene expression are needed in
order to clarify which are directly involved in successful viral response, in what capacity they affect
response, and if pharmacotherapy directed at induction of interferon stimulated genes can help
improve treatment response.
Hepatitis B
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Chronic HBV infection can be successfully treated with IFN monotherapy.[39] Loss of viral DNA
and antibody formation are successful outcomes associated with IFN treatment. The mechanism of IFN
antiviral activity varies depending on HBeAg-positive or HBeAg-negative disease. In HBeAg-positive
patients, an immune response is stimulated by IFN whereas in HBeAg-negative disease, IFN acts directly
as an antiviral.[5] HBeAg-negative disease tends to be more difficult to treat and is associated with a
longer duration of disease and a higher likelihood of complications such as cirrhosis.[20] A number of
oral non-nucleoside reverse transcriptase inhibitors are also available for treatment of HBV (entecavir,
tenofovir, adefovir, lamivudine, and telbivudine). Although IFN is still considered a first line alternative
and provides the advantage of defined treatment duration rather than potentially lifelong
administration, these oral agents are often used in therapy because of their ease of use and reduced
number of side effects associated with treatment.
Hepatitis C
The ability of HCV to evade the host immune response has produced a complex RNA virus
capable of lingering infection, ultimately resulting in opportunities for increased risk of transmission and
complications from advanced liver disease. Much of the research regarding the use of IFN for chronic
viral hepatitis has focused on use in HCV. Following treatment with IFN, a decline in HCV RNA occurs
over several phases. A rapid inhibition of RNA production within the first 1-2 days of treatment is
followed by a second, slower phase associated with clearance of infected cells.[23, 40, 41] The immune
response to endogenous IFN produced by innate immunity and that administered exogenously can differ
in terms of antiviral activities based on the phase of viral decline.
Studies have shown that response to IFN based treatment for HCV may be affected by
differences in IFN signaling and induction. It is likely that HCV has mechanisms to avoid recognition by
the innate immune response, and as such inhibits the ability of HCV-infected cells to generate IFN.[25,
8

38, 42] Early studies conducted in non-responders to current therapy showed wide genetic diversity
with many showing no common traits to predict non-response to IFN therapy.[25, 38, 43]
However, in 2009, several major studies were published associating a single nucleotide
polymorphism (SNP) just upstream from interleukin-28B gene (IL28B) with IFN response in patients with
HCV genotype 1.[44-48] Additional evidence points to the fact that the IL28B polymorphism is also
linked to spontaneous clearance of HCV.[48, 49] The IL28B variant encodes for IFN-λ3, a type III IFN
belonging to the IL-10 superfamily, which function in a manner similar to type I IFNs resulting in
interferon stimulated gene induction.[49-51]
The genome-wide association study conducted by Ge et al. evaluated over 1600 treatmentnaïve HCV genotype 1 patients, the majority of which originated from the IDEAL study.[45] Results from
logistic regression showed that the IL28B polymorphism was a stronger predictor of SVR than baseline
viral load, ethnicity or degree of fibrosis. Further research in this area is needed to clearly identify a
future role for genotype testing and further clarify whether it may influence response to therapy in
other HCV genotypes.
A multicenter, randomized controlled study by Mangia et al. analyzed 268 Caucasian patients
with HCV genotype 2 (n=213) and 3 (n=55). Out of 61% of patients that achieved rapid virologic
response (RVR), IL28B genotype was not associated with SVR, whereas in those patients who did not
achieve RVR, a significant difference in SVR was noted based on IL28B genotype.[52] At this time,
genotype testing for IL28B is not routinely recommended for all HCV patients planning to undergo
treatment, but it may be in the future. If done, it should not be used as the only factor when choosing a
treatment strategy.[49]
Investigational IFN Therapies
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The complexity of viral defense mechanisms and subsequent effect on the host response has led
not only to development of chronic infections but also to a lack of a viable vaccine. HCV viral polymerase
lacks a proofreading capability, creating a more diverse target for vaccine development.[18] Additional
challenges include the lack of a suitable animal model to mimic a human environment and medium for
viral growth.[18]
One of the major limitations to IFN therapy is adverse effects. Malaise, gastrointestinal effects,
neuropsychiatric effects, neutropenia, and anemia can all limit the effectiveness of treatment by
necessitating dosage reductions or treatment discontinuation. For newer IFN therapies to be successful,
they must induce an antiviral response while at the same time limit adverse effects.
Albinterferon is a new IFN therapy currently in development for the treatment of chronic HCV.
This product is a combination of interferon α-2b fused to recombinant human albumin. One of the
advantages with this product is that it only requires once or twice monthly dosing.[53] Not much is
known at this time about the immunomodulating effects of albinterferon in HCV. It has been shown to
have similar SVR and adverse event rates to traditional peg-IFN when used in combination with
ribavirin.[54-56]
Research into lambda IFN as an agent to treat HCV has also been initiated. It is hypothesized
that lambda IFNs may be associated with less adverse effects over IFN-α because IFN-λ receptors are
primarily found in hepatocytes.[49, 57] Specifically, research into new investigational pharmacotherapy
in the form of pegylated IL-29 (IFN-λ1) in patients with HCV genotype 1 who relapsed following
traditional treatment with peg-IFN-α and ribavirin appears promising.[50, 57] Both IFN-λ1 and IFN-λ3
share a common receptor and have a similar sequence identity. [57]
A four week, open-label study conducted in 56 patients with chronic HCV genotype 1 was
designed to assess peg-IFN- λ1 in combination with ribavirin.[57] It was a dose escalation study
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conducted in three parts. Parts 1 and 2 evaluated patients that relapsed following treatment with IFN-α,
and part 3 included treatment-naïve patients. In part 1, pegylated lambda interferon monotherapy (1.5
µg/kg or 3 µg/kg) was administered subcutaneously every 2 weeks or weekly. In parts 2 and 3, a range of
peg-IFN-λ dosages (0.5 µg/kg, 0.75 µg/kg, 1.5 µg/kg or 2.25 µg/kg) were administered weekly in
combination with ribavirin twice daily (1000 mg for weight < 75 kg and 1200 mg if weight ≥ 75 kg). The
primary outcomes were safety and tolerability. Pharmacokinetics and viral load reduction were
evaluated as secondary endpoints.
Commonly reported adverse effects with PEG IFN-λ included fatigue (29%), nausea (12%),
myalgia (11%) and headache (9%). Most adverse events were mild or moderate in severity. Four patients
(7%) experienced treatment-related toxicity and required doses to be withheld. One patient
experienced grade 3 thrombocytopenic purpura and another patient had elevated ALT, AST and bilirubin
levels. Both events were considered to be related to treatment with peg-IFN-λ. Aminotransferase
elevations occurred most often in patients who received high dose (3 µg/kg) PEG IFN-λ monotherapy.
No clinically relevant decreases in absolute neutrophil count occurred. Also, hemoglobin values
remained consistent with known effects in patients that received ribavirin therapy. Viral activity
decreased in the majority of patients that relapsed with previous treatment, with 23 of 24 patients
achieving at least a > 2-log reduction in HCV RNA. Six of 7 treatment-naïve patients achieved a similar
reduction in viral load and 2 achieved undetectable HCV RNA levels. Kinetic data showed a linear
relationship between dose and exposure independent of body weight, which may prompt future
research into a evaluating a fixed dose of peg-IFN-λ.[57]
Larger, longer, controlled and blinded studies of lambda IFN as a viable treatment option in HCV
are needed in order to define its place in therapy and benefits over existing IFN therapy. Studies in other
HCV genotypes are also needed. Additionally, with the advent of protease inhibitors, more research will
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be necessary to evaluate how direct antivirals and IL28B genotyping interact in guiding treatment
decisions.
Adjunctive therapy with agents that induce or restore interferon stimulated gene expression has
recently been evaluated in patients with HCV. S-adenosyl methionine (SAMe) given orally was evaluated
in an open-label study in 24 patients with chronic HCV, genotype 1 who were considered nonresponders to previous IFN and ribavirin treatment.[41] SAMe was administered at a dose of 800 mg
twice daily in combination with peginterferon alfa-2a (180 µg/kg weekly) and weight-based ribavirin
(1000 mg for weight < 75 kg and 1200 mg if weight ≥ 75 kg). The primary outcome was change in first
and second phase viral decline. Treatment response and interferon stimulated gene expression were
also evaluated after up to 72 weeks of treatment. Results showed significant improvement in second
phase viral decline assessed at 2 weeks. Sustained virologic response (SVR) was also evaluated; however,
this study was not powered to detect differences in virologic response rates. Furthermore, at the time of
publication, not all patients had reached 24 weeks post-treatment so the full effects on sustained
virologic response (SVR) were not fully known. The addition of SAMe showed greater induction of
interferon stimulated genes including, viperin, myxovirus resistance protein and ISG15, compared to
control. Adverse effects noted with SAMe were mild and mostly related to gastrointestinal upset, likely
as a result of lactose in the tablet preparation.[41]
Additional research is aimed at investigating structure-activity relationships and preliminary
pharmacokinetic studies into oral IFN inducers that act on TLRs in the treatment of HCV.[58]
Use of interferons for respiratory virus infection
Upper respiratory tract infection in the form of “the common cold” can be caused by a variety of
viruses including rhinovirus, coronavirus, influenza, parainfluenza, respiratory syncytial virus,
adenovirus, coxsackie, and echovirus families among others.[59] Symptoms may include rhinorrhea,
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nasal obstruction, cough, fever, and sore throat. The disease is usually mild and self-limited, but a
number of trials have addressed treatment or prevention of the common cold with therapeutic agents.
Interferons were once one of the most popular prospects for this purpose, but the little benefit that was
derived from them was counteracted by the adverse effects inflicted.[60]
An early double-blind trial with IFN-α-2b intranasal drops did demonstrate that with use for
several days prior to experimentally induced rhinovirus infection, common cold symptoms were
significantly less in study participants compared to placebo drop users.[61] Administration of the drops
four times daily was superior to a higher dose given once daily at preventing infection. Short-term use
was well-tolerated, but obviously it is not realistic for everyone to use intranasal drops four times daily
throughout the entire cold season. In an attempt to prevent natural infection during the period of
increased acute respiratory tract virus activity, a twice daily nasal spray was studied in volunteers over
28 days.[62] There was a significant decrease in the number of rhinovirus infections noted, but not in
any other types of viral respiratory tract infections including parainfluenza. Adverse events with the
interferon formulation were quite common in this placebo-controlled trial. During the first week alone,
20% of participants receiving interferon spray reported nosebleeds. This number increased to 41% by
the end of the study.
Providing interferon prophylaxis for family members of those infected with common cold viruses
is a more targeted approach to therapy. Several studies have addressed the usefulness of IFN nasal
sprays in this scenario. Seven days of use did significantly reduce rhinovirus infections in two different
trials when compared to placebo for both individuals (7.9% vs 15.5%) and their families (3.3% vs. 33.3%,
both p<0.05), but not in two other studies when lower doses were given for a shorter five day course.
[63-66] Overall, the intranasal dose of interferon needed to protect against upper respiratory tract
infection appears to cause significant unwanted effects.[67] Infection with coronavirus and respiratory
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syncytial virus has also been an object of investigation for IFN-α-2b nasal sprays, but with little
success.[68, 69] A study of intranasal human lymphoblastoid IFN-α-n1 (Wellferon) suggested lower
prophylactic activity for influenza than it did for rhinovirus.[70]
Since results of prophylactic trials with interferons for common cold viruses were not favorable,
use in the treatment of infection seemed a logical application for this biological response modifier.
Although some benefit was originally seen with twice daily IFN-α-2b intranasal drops for treatment of
experimentally induced rhinovirus[71], no advantage was clear when an intranasal spray was used once
daily for five days to treat natural infection.[72] Increased rates of blood in the mucus were again noted
for participants receiving the intervention plus the interferon group experienced more secondary
complications requiring prescription of antibiotics. The authors concluded that intranasal interferon was
ineffective for treating the common cold and it was associated with clinically significant side effects.
Similar trials with IFN-β-serine and IFN-γ formulations, although initially positive, have shown
equally disappointing clinical results.[73-76] Even though the prospects of further study on interferons
for upper respiratory tract infection appear limited, one modern trial did demonstrate an added benefit
of intranasal IFNα-2b in combination with an antihistamine (chlorpheniramine) and non-steroidal antiinflammatory drug (ibuprofen) at reducing common cold symptoms – showing at least one group is still
interested in studying the topic.[77] Investigators have also recently begun research on an alternative
therapeutic approach for rhinovirus infections using the IFN and TNFα-inducer, imiquimod. Application
of this intranasal cream in primates has shown promising results in terms of enhancing cytokine
response, but human trials have not yet been published.[78]
Use of interferons for genital infections and warts
Human papillomoviruses (HPV) are now known to be the cause of cervical cancer and are also
responsible for genital warts. They are non-enveloped, double-stranded DNA viruses that invade
14

mucosal and epithelial tissues during sexual contact with an infected partner. It is estimated that over
50% of the sexually active American population has been or will be infected with HPV at one point in
their lives.[79] When hyperproliferation of infected cells occurs, this can lead to genital warts or cancer
of the cervix, vagina, vulva and penis among others. There are over 100 different types of HPV and
approximately 40 of them infect genital mucosa. Fifteen carcinogenic types of HPV have been
identified, but two of them are associated with 70% of cervical cancers.[80] Two vaccines have recently
been introduced which prevent infection with these most common high-risk types of HPV, 16 and
18.[81] One of these vaccines can also induce protection against the most prevalent HPV types that
have a low-risk of malignancy, but instead cause genital warts - 6 and 11.
HPV has the ability to persist in stratified epithelia for decades because of mechanisms that
avoid immune eradication. Interferon plays a large role in this cycle.[82] Interferons are normally
secreted by keratinocytes, but HPV reduces their expression. Introduction of low level IFN can actually
increase early gene transcription and HPV replication which may explain why use of the agent
therapeutically has had mixed results.[83] Overall outcomes have been positive more often for cases of
genital warts than reduction of HPV lesions associated with cancers. A study comparing the in vitro
activity of IFN-α-2b and IFN-α-n3 on oncogenic HPV 16, 18, and 31b demonstrated that increasing
concentrations did not always correlate with a stepwise inhibition of HPV replication.[84] Meanwhile, a
meta-analysis recently analyzed locally-used and systemic interferon for genital warts.[85] Seven
randomized studies of inferferon intralesional injection or topical gel met criteria for inclusion and
overall there was a benefit in complete response rates over placebo (44.4% vs. 16.15%, RR 2.68, 95% CI
1.79 to 4.02). However there was not a difference in outcomes for trials comparing systemic interferons
to placebo. In comparison, clearance of genital and perianal warts occurs in 50% of patients with the
topical IFN-inducer, imiquimod, usually after 8-10 weeks of use.[3] The 5% imiquimod cream (Aldara®)
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should be applied to affected areas three times a week for up to 16 weeks while the newer 3.75% cream
(Zyclara) can be applied once daily for as little as 8 weeks to treat external genital warts caused by HPV.
Systemic interferon therapy may be useful when HPV affects areas of the body other than the
anogenital region.[86] Successful treatment with systemic PEG IFN-α and a topical retinoid has been
reported for mucosal carcinomas from epidermodysplasia verruciformis, a genetic abnormality leading
to persistent and widespread HPV infection of the skin.[87] Recurrent respiratory HPV infection has also
been effectively treated with IFN-α (12 out of 18 patients), although it had no effect on viral load or
replication.[88] A 20-year follow-up of patients treated with IFN-α for recurrent respiratory
papillomatosis confirmed better response rates for HPV-6 than type 11 which had a higher likelihood of
malignant transformation.[89] For recurrent conjunctival papilloma, topical plus systemic or
intralesional IFN has been effective with partial excision.[90, 91] The rapid resolution of significant HPVassociated warts on the hand, foot and face has also occurred in an HIV-infected patient on
antiretrovirals while being treated for hepatitis C with PEG IFNα-2b and ribavirin.[92]
Case reports of treatment with the topical interferon inducer, imiquimod, have shown promise
for its use in focal epithelial hyperplasia (Heck disease), a rare disorder caused by specific types of HPV
(13, 14, 32, and 55) affecting oral mucosa primarily in children.[93] In addition to that, imiquimod 5%
cream has been used successfully in the treatment of plantar warts, a smoother, flatter manifestation of
HPV 1, 2, and 4 on the foot.[94] Interestingly the oral H2-antagonist cimetidine, along with reducing
stomach acid, also induces production of IFN-γ and interleukin-2 which eliminates viral warts in some
patients.[95] In the future, the improved application of more effective topical interferons may become a
reality.[96] This could provide a valuable treatment for HPV infections without the systemic side effects
of current injectable formulations.
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Use of interferons as vaccine adjuvants
Adjuvants (adjuvare, Latin for “to help”) are substances that augment the immunogenicity of an
antigen when mixed with the antigen for use in a vaccine. Adjuvants 1) stimulate granuloma (which is a
macrophage-rich mass), 2) enhance co-stimulatory signals, 3) stimulate nonspecific lymphocyte
production, 4) prolong the antigen concentration in a site for lymphocyte exposure [97] and 5) induce
cytokines [2, 98]
Research in vaccine development has shown that one of the most promising uses of IFNs is as an
adjuvant with specific antigens in prophylactic vaccines.[99] Toporovski et al. provides a current review
of the use of IFN-α, IFN-β, IFN-γ, and IFN- λ in vaccine studies that focus primarily on murine, avian,
porcine, and non-human species. Regardless of the species, the use of interferons as adjuvants seems to
improve the efficacy and safety of most vaccines while providing the immunomodulatory effect of
stimulating the T-helper 1 response.[99]
In humans, IFN-α, predominantly produced by plasmacytoid dendritic cells, plays a large role in
the body’s immune response against viruses. [100] It induces plasma cell differentiation from B-cells,
causing an increase in the serum level of influenza specific immunoglobulins and channels antigen
presenting cells (APC’s) to the site of infection.[101] Most research on IFN-α adjuvant activity and its
subsequent use in approved vaccines seems to indicate that it is a potent adjuvant.[99] When mixed
with the influenza vaccine and injected intramuscularly, it is a highly effective adjuvant.[100]
Oromucosal administration of recombinant IFN-α, like that of natural oromucosal IFN production, has
been shown to provide immunity against viral infection and tumor cell growth. [102] Non- or lowresponders to a previous vaccine showed an improved immunoglobulin response with a recombinant
IFN-α and HBV vaccine.[103]
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While research is also focused on the other classes of IFNs as adjuvants, thus far they haven’t
yielded results as promising as that of IFN-α. The use of IFN-β has yielded mixed results; IFN-γ has been
used primarily in DNA vaccines; even less is known about the use of IFN-λ in vaccines.[99] Nevertheless,
the use of IFNs as adjuvants shows great promise in augmenting vaccine efficiency and should continue
to be a top priority in the development of vaccines.
Conclusion
Interferons have been tested repeatedly against infectious diseases, but injections are used
mostly for the treatment of viral hepatitis C and prevention of infections in patients with chronic
granulomatous disease clinically. Intralesional IFN and topical inducers are effective for reducing the
manifestations of genital warts, but they do not eliminate cancer-causing HPV from the body. IFN has
not proven to be consistently effective for treatment of respiratory tract infections from the common
cold or influenza viruses and prophylactic use is not currently feasible. The severity and quantity of
adverse effects from systemic IFN therapy make it unattractive for many uses. Several infections,
including herpes simplex, herpes zoster, cytomegalovirus and even viral hepatitis B have other effective
pharmacological treatments. IFN has been successfully utilized as a vaccine adjuvant and further
research may allow for additional use of it for that application in the future.

18

References
1

Goering RV, Dockrell HM, Zuckerman M, Wakelin D, Roitt IM, Mims C et al. Mim's medical
microbiology. 4th edition'. Philadelphia: Elsevier Limited; 2008.

2

Male D, Brostoff J, Roth D and Roitt I. Immunology. 7th edition'. Philadelphia: Elsevier Limited;
2006.

3

Hayden FG. Antiviral agents. In: Brunton LL, Lazo JS and K.L. P, editors. Goodman & gilman's the
pharmacological basis of therapeutics, 11th edition. New York: McGraw-Hill; 2006. p. 1225-42.

4

Mullangi P, Shahani L and Koirala J. Role of endogenous biological response modifiers in
pathogenesis of infectious diseases. Infectious Disease Clinics of North America 2011: In Press.

5

Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR et al. Interferons at age 50:
Past, current and future impact on biomedicine. Nat Rev Drug Discov 2007;6(12):975-90.

6

Hodson EM, Jones CA, Strippoli GF, Webster AC and Craig JC. Immunoglobulins, vaccines or
interferon for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane
Database Syst Rev 20072):CD005129.

7

Houglum JE. Interferon: Mechanisms of action and clinical value. Clin Pharm 1983;2(1):20-8.

8

Sakai Y, Ohga S, Tonegawa Y, Takada H, Nakao F, Nakayama H et al. Interferon-alpha therapy for
chronic active epstein-barr virus infection: Potential effect on the development of tlymphoproliferative disease. J Pediatr Hematol Oncol 1998;20(4):342-6.

9

Fda authorizes alferon ldo clinical study for treatment ad prevention of influenza. Hemispherx
Biopharma, Inc. Press Release. Available at: http://www.drugs.com/news/fda-authorizesalferon-ldo-clinical-study-prevention-influenza-28692.html. Accessed Apr 25, 2011.

10

Alston B, Ellenberg JH, Standiford HC, Muth K, Martinez A, Greaves W et al. A multicenter,
randomized, controlled trial of three preparations of low-dose oral alpha-interferon in hiv-

19

infected patients with cd4+ counts between 50 and 350 cells/mm(3). Division of aids treatment
research initiative (datri) 022 study group. J Acquir Immune Defic Syndr 1999;22(4):348-57.
11

Fitzgibbon JE and John JF. In vitro activity of interferon-alpha n3 (alferon n) against hiv-1.
Interscience Conference on Antimicrobial Agents and Chemotherapy, vol 38). San Diego, CA:
American Society of Microbiology; 1998. p. 367 (abstract no. I-13).

12

Hoffman-laroche inc. Pegasys® (peg-interferon alfa-2a) package insert. Nutley, NJ; 2010.

13

Schering corporation. Peg-intron® (peginterferon afla-2b) package insert. Kenilworth, NJ; 2010.

14

A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease.
The international chronic granulomatous disease cooperative study group. N Engl J Med
1991;324(8):509-16.

15

Marciano BE, Wesley R, De Carlo ES, Anderson VL, Barnhart LA, Darnell D et al. Long-term
interferon-gamma therapy for patients with chronic granulomatous disease. Clin Infect Dis
2004;39(5):692-9.

16

Rao S, Blessman D, Koirala J, Goodrich J and Khardori N. Biological response modifiers as adjunct
treatment for refractory localized mycobacterium avium complex infections. Journal of
Investigative Medicine. 2005;53(S2):S398.

17

Hepatitis b. Fact sheet. World Health Organization. Available at:
http://www.who.int/vaccine_research/diseases/viral_cancers/en/index2.html Accessed Mar 24,
2011.

18

Initiative for vaccine research. Viral cancers. World Health Organization. Available at:
http://www.who.int/vaccine_research/diseases/viral_cancers/en/index2.html Accessed Apr 6,
2011.

19

Daniels D, Grytdal S and Wasley A. Surveillance for acute viral hepatitis - united states, 2007.
MMWR Surveill Summ 2009;58(3):1-27.

20

20

Aoki FA, Hayden FG and Dolin R. Antiviral drugs (other than antiretrovirals). In: Mandell GL,
Bennett JE and Dolin R, editors. Principles and practices of infectious diseases, vol 1).
Philadelphia, PA: Churchill Livingstone Elsevier; 2010. p. 565-610.

21

Crotta S, Ronconi V, Ulivieri C, Baldari CT, Valiante NM, Abrignani S et al. Cytoskeleton
rearrangement induced by tetraspanin engagement modulates the activation of t and nk cells.
Eur J Immunol 2006;36(4):919-29.

22

Golden-Mason L and Rosen HR. Natural killer cells: Primary target for hepatitis c virus immune
evasion strategies? Liver Transpl 2006;12(3):363-72.

23

Stegmann KA, Bjorkstrom NK, Veber H, Ciesek S, Riese P, Wiegand J et al. Interferon-alphainduced trail on natural killer cells is associated with control of hepatitis c virus infection.
Gastroenterology 2010;138(5):1885-97.

24

Wedemeyer H, He XS, Nascimbeni M, Davis AR, Greenberg HB, Hoofnagle JH et al. Impaired
effector function of hepatitis c virus-specific cd8+ t cells in chronic hepatitis c virus infection. J
Immunol 2002;169(6):3447-58.

25

Wada M, Marusawa H, Yamada R, Nasu A, Osaki Y, Kudo M et al. Association of genetic
polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis c
patients. J Viral Hepat 2009;16(6):388-96.

26

He XH, Shaw PC and Tam SC. Reducing the immunogenicity and improving the in vivo activity of
trichosanthin by site-directed pegylation. Life Sci 1999;65(4):355-68.

27

Shiffman ML. Pegylated interferons: What role will they play in the treatment of chronic
hepatitis c? Curr Gastroenterol Rep 2001;3(1):30-7.

28

Feld JJ, Lutchman GA, Heller T, Hara K, Pfeiffer JK, Leff RD et al. Ribavirin improves early
responses to peginterferon through improved interferon signaling. Gastroenterology
2010;139(1):154-62 e4.

21

29

Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S et al. Boceprevir for
previously treated chronic hcv genotype 1 infection. N Engl J Med 2011;364(13):1207-17.

30

Berman K and Kwo PY. Boceprevir, an ns3 protease inhibitor of hcv. Clin Liver Dis
2009;13(3):429-39.

31

Lawitz E, Rodriguez-Torres M, Muir AJ, Kieffer TL, McNair L, Khunvichai A et al. Antiviral effects
and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis c patients. J
Hepatol 2008;49(2):163-9.

32

Forestier N, Reesink HW, Weegink CJ, McNair L, Kieffer TL, Chu HM et al. Antiviral activity of
telaprevir (vx-950) and peginterferon alfa-2a in patients with hepatitis c. Hepatology
2007;46(3):640-8.

33

Sarrazin C, Rouzier R, Wagner F, Forestier N, Larrey D, Gupta SK et al. Sch 503034, a novel
hepatitis c virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1
nonresponders. Gastroenterology 2007;132(4):1270-8.

34

McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R et al. Telaprevir
with peginterferon and ribavirin for chronic hcv genotype 1 infection. N Engl J Med
2009;360(18):1827-38.

35

Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T et al. Telaprevir and peginterferon
with or without ribavirin for chronic hcv infection. N Engl J Med 2009;360(18):1839-50.

36

Fitzgerald KA. The interferon inducible gene: Viperin. J Interferon Cytokine Res 2011;31(1):1315.

37

Jiang D, Guo H, Xu C, Chang J, Gu B, Wang L et al. Identification of three interferon-inducible
cellular enzymes that inhibit the replication of hepatitis c virus. J Virol 2008;82(4):1665-78.

38

Pfeffer LM, Madey MA, Riely CA and Fleckenstein JF. The induction of type i interferon
production in hepatitis c-infected patients. J Interferon Cytokine Res 2009;29(5):299-306.

22

39

Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER et al. A treatment algorithm
for the management of chronic hepatitis b virus infection in the united states: 2008 update. Clin
Gastroenterol Hepatol 2008;6(12):1315-41; quiz 286.

40

Herrmann E, Lee JH, Marinos G, Modi M and Zeuzem S. Effect of ribavirin on hepatitis c viral
kinetics in patients treated with pegylated interferon. Hepatology 2003;37(6):1351-8.

41

Feld JJ, Modi AA, El-Diwany R, Rotman Y, Thomas E, Ahlenstiel G et al. S-adenosyl methionine
improves early viral responses and interferon-stimulated gene induction in hepatitis c
nonresponders. Gastroenterology 2011;140(3):830-9.

42

Meurs EF and Breiman A. The interferon inducing pathways and the hepatitis c virus. World J
Gastroenterol 2007;13(17):2446-54.

43

Cuevas JM, Torres-Puente M, Jimenez-Hernandez N, Bracho MA, Garcia-Robles I, Wrobel B et al.
Genetic variability of hepatitis c virus before and after combined therapy of interferon plus
ribavirin. PLoS One 2008;3(8):e3058.

44

Jensen DM. A new era of hepatitis c therapy begins. N Engl J Med 2011;364(13):1272-4.

45

Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ et al. Genetic variation in il28b
predicts hepatitis c treatment-induced viral clearance. Nature 2009;461(7262):399-401.

46

Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML et al. Il28b is associated
with response to chronic hepatitis c interferon-alpha and ribavirin therapy. Nat Genet
2009;41(10):1100-4.

47

Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N et al. Genome-wide
association of il28b with response to pegylated interferon-alpha and ribavirin therapy for
chronic hepatitis c. Nat Genet 2009;41(10):1105-9.

48

Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C et al. Genetic variation in il28b and
spontaneous clearance of hepatitis c virus. Nature 2009;461(7265):798-801.

23

49

Afdhal NH, McHutchison JG, Zeuzem S, Mangia A, Pawlotsky JM, Murray JS et al. Hepatitis c
pharmacogenetics: State of the art in 2010. Hepatology 2011;53(1):336-45.

50

Liapakis A and Jacobson I. Pharmacogenetics of hepatitis c therapy. Pharmacogenomics
2010;11(2):135-9.

51

Shackel NA, Bowen DG and McCaughan GW. Snipping away at hepatitis c. Hepatology
2010;51(2):703-5.

52

Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K et al. An il28b
polymorphism determines treatment response of hepatitis c virus genotype 2 or 3 patients who
do not achieve a rapid virologic response. Gastroenterology 2010;139(3):821-7, 27 e1.

53

Zeuzem S, Yoshida EM, Benhamou Y, Pianko S, Bain VG, Shouval D et al. Albinterferon alfa-2b
dosed every two or four weeks in interferon-naive patients with genotype 1 chronic hepatitis c.
Hepatology 2008;48(2):407-17.

54

Bain VG, Kaita KD, Marotta P, Yoshida EM, Swain MG, Bailey RJ et al. Safety and antiviral activity
of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis c patients. Clin
Gastroenterol Hepatol 2008;6(6):701-6.

55

Nelson DR, Benhamou Y, Chuang WL, Lawitz EJ, Rodriguez-Torres M, Flisiak R et al. Albinterferon
alfa-2b was not inferior to pegylated interferon-alpha in a randomized trial of patients with
chronic hepatitis c virus genotype 2 or 3. Gastroenterology 2010;139(4):1267-76.

56

Zeuzem S, Sulkowski MS, Lawitz EJ, Rustgi VK, Rodriguez-Torres M, Bacon BR et al. Albinterferon
alfa-2b was not inferior to pegylated interferon-alpha in a randomized trial of patients with
chronic hepatitis c virus genotype 1. Gastroenterology 2010;139(4):1257-66.

57

Muir AJ, Shiffman ML, Zaman A, Yoffe B, de la Torre A, Flamm S et al. Phase 1b study of
pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1
hepatitis c virus infection. Hepatology 2010;52(3):822-32.

24

58

Tran TD, Pryde DC, Jones P, Adam FM, Benson N, Bish G et al. Design and optimisation of orally
active tlr7 agonists for the treatment of hepatitis c virus infection. Bioorg Med Chem Lett
2011;21(8):2389-93.

59

Turner RB. The common cold. In: Mandell GL, Bennett JE and Dolin R, editors. Principles and
practices of infectious diseases. Philadelphia, PA: Churchill Livingston Elsevier; 2010.

60

Enlow ML and Haley CJ. Alpha 2-interferon for the common cold. Ann Pharmacother
1992;26(3):345-7.

61

Hayden FG and Gwaltney JM, Jr. Intranasal interferon alpha 2 for prevention of rhinovirus
infection and illness. J Infect Dis 1983;148(3):543-50.

62

Monto AS, Shope TC, Schwartz SA and Albrecht JK. Intranasal interferon-alpha 2b for seasonal
prophylaxis of respiratory infection. J Infect Dis 1986;154(1):128-33.

63

Douglas RM, Moore BW, Miles HB, Davies LM, Graham NM, Ryan P et al. Prophylactic efficacy of
intranasal alpha 2-interferon against rhinovirus infections in the family setting. N Engl J Med
1986;314(2):65-70.

64

Hayden FG, Albrecht JK, Kaiser DL and Gwaltney JM, Jr. Prevention of natural colds by contact
prophylaxis with intranasal alpha 2-interferon. N Engl J Med 1986;314(2):71-5.

65

Monto AS, Schwartz SA and Albrecht JK. Ineffectiveness of postexposure prophylaxis of
rhinovirus infection with low-dose intranasal alpha 2b interferon in families. Antimicrob Agents
Chemother 1989;33(3):387-90.

66

Herzog C, Berger R, Fernex M, Friesecke K, Havas L, Just M et al. Intranasal interferon (rifn-alpha
a, ro 22-8181) for contact prophylaxis against common cold: A randomized, double-blind and
placebo-controlled field study. Antiviral Res 1986;6(3):171-6.

67

Scott GM, Onwubalili JK, Robinson JA, Dore C, Secher DS and Cantell K. Tolerance of one-month
intranasal interferon. J Med Virol 1985;17(2):99-106.

25

68

Turner RB, Felton A, Kosak K, Kelsey DK and Meschievitz CK. Prevention of experimental
coronavirus colds with intranasal alpha-2b interferon. J Infect Dis 1986;154(3):443-7.

69

Higgins PG, Barrow GI, Tyrrell DA, Isaacs D and Gauci CL. The efficacy of intranasal interferon
alpha-2a in respiratory syncytial virus infection in volunteers. Antiviral Res 1990;14(1):3-10.

70

Phillpotts RJ, Higgins PG, Willman JS, Tyrrell DA, Freestone DS and Shepherd WM. Intranasal
lymphoblastoid interferon ("wellferon") prophylaxis against rhinovirus and influenza virus in
volunteers. J Interferon Res 1984;4(4):535-41.

71

Hayden FG and Gwaltney JM, Jr. Intranasal interferon-alpha 2 treatment of experimental
rhinoviral colds. J Infect Dis 1984;150(2):174-80.

72

Hayden FG, Kaiser DL and Albrecht JK. Intranasal recombinant alfa-2b interferon treatment of
naturally occurring common colds. Antimicrob Agents Chemother 1988;32(2):224-30.

73

Sperber SJ, Levine PA, Innes DJ, Mills SE and Hayden FG. Tolerance and efficacy of intranasal
administration of recombinant beta serine interferon in healthy adults. J Infect Dis
1988;158(1):166-75.

74

Sperber SJ, Levine PA, Sorrentino JV, Riker DK and Hayden FG. Ineffectiveness of recombinant
interferon-beta serine nasal drops for prophylaxis of natural colds. J Infect Dis 1989;160(4):7005.

75

Higgins PG, Al-Nakib W, Willman J and Tyrrell DA. Interferon-beta ser as prophylaxis against
experimental rhinovirus infection in volunteers. J Interferon Res 1986;6(2):153-9.

76

Higgins PG, al-Nakib W, Barrow GI and Tyrrell DA. Recombinant human interferon-gamma as
prophylaxis against rhinovirus colds in volunteers. J Interferon Res 1988;8(5):591-6.

77

Gwaltney JM, Jr., Winther B, Patrie JT and Hendley JO. Combined antiviral-antimediator
treatment for the common cold. J Infect Dis 2002;186(2):147-54.

26

78

Clejan S, Mandrea E, Pandrea IV, Dufour J, Japa S and Veazey RS. Immune responses induced by
intranasal imiquimod and implications for therapeutics in rhinovirus infections. J Cell Mol Med
2005;9(2):457-61.

79

Genital hpv infection - fact sheet. Centers for Disease Control and Prevention. Available at:
http://www.cdc.gov/std/HPV/STDFact-HPV.htm. Accessed Apr 25, 2011.

80

Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV et al. Epidemiologic
classification of human papillomavirus types associated with cervical cancer. N Engl J Med
2003;348(6):518-27.

81

Bergman SJ and Collins-Lucey E. Update on human papillomavirus vaccines: Life saver or
controversy magnet? Clinical Microbiology Newsletter 2011:In Press.

82

Beglin M, Melar-New M and Laimins L. Human papillomaviruses and the interferon response. J
Interferon Cytokine Res 2009;29(9):629-35.

83

Lace MJ, Anson JR, Klingelhutz AJ, Harada H, Taniguchi T, Bossler AD et al. Interferon-beta
treatment increases human papillomavirus early gene transcription and viral plasmid genome
replication by activating interferon regulatory factor (irf)-1. Carcinogenesis 2009;30(8):1336-44.

84

Sen E, McLaughlin-Drubin M and Meyers C. Efficacy of two commercial preparations of
interferon-alpha on human papillomavirus replication. Anticancer Res 2005;25(2A):1091-100.

85

Yang J, Pu Y-g, Zeng Z-m, Yu Z-j, Huang N and Deng Q-w. Interferon for the treatment of genital
warts: A systematic review. BMC Infect Dis 2009;9(1):156.

86

Shrestha NK and Hamrock DJ. Successful treatment of disseminated human papillomavirus
infection with pegylated interferon and ribavirin. Clin Infect Dis 2010;51(1):e4-6.

87

Gubinelli E, Posteraro P, Cocuroccia B and Girolomoni G. Epidermodysplasia verruciformis with
multiple mucosal carcinomas treated with pegylated interferon alfa and acitretin. J Dermatolog
Treat 2003;14(3):184-8.

27

88

Szeps M, Dahlgren L, Aaltonen LM, Ohd J, Kanter-Lewenshon L, Dahlstrand H et al. Human
papillomavirus, viral load and proliferation rate in recurrent respiratory papillomatosis in
response to alpha interferon treatment. The Journal of general virology 2005;86(Pt 6):1695-702.

89

Gerein V, Rastorguev E, Gerein J, Jecker P and Pfister H. Use of interferon-alpha in recurrent
respiratory papillomatosis: 20-year follow-up. Ann Otol Rhinol Laryngol 2005;114(6):463-71.

90

de Keizer RJ and de Wolff-Rouendaal D. Topical alpha-interferon in recurrent conjunctival
papilloma. Acta Ophthalmol Scand 2003;81(2):193-6.

91

Kothari M, Mody K and Chatterjee D. Resolution of recurrent conjunctival papilloma after topical
and intralesional interferon alpha2b with partial excision in a child. J Aapos 2009;13(5):523-5.

92

Pavan MH, Velho PE, Vigani AG, Goncalves FL, Jr. and Aoki FH. Treatment of human
papillomavirus with peg-interferon alfa-2b and ribavirin. Braz J Infect Dis 2007;11(3):383-4.

93

Yasar S, Mansur AT, Serdar ZA, Goktay F and Aslan C. Treatment of focal epithelial hyperplasia
with topical imiquimod: Report of three cases. Pediatr Dermatol 2009;26(4):465-8.

94

Zamiri M and Gupta G. Plantar warts treated with an immune response modifier: A report of
two cases. Clin Exp Dermatol 2003;28 (Suppl 1):45-7.

95

Mitsuishi T, Iida K and Kawana S. Cimetidine treatment for viral warts enhances il-2 and ifngamma expression but not il-18 expression in lesional skin. Eur J Dermatol 2003;13(5):445-8.

96

Foldvari M, Badea I, Kumar P, Wettig S, Batta R, King MJ et al. Topical delivery of interferon
alpha in human volunteers and treatment of patients with human papillomavirus infections.
Curr Drug Deliv 2011.

97

Kuby J. Immunology. New York: W.H. Freeman and Co.; 1997.

98

Singh M and O'Hagan D. Advances in vaccine adjuvants. Nat Biotechnol 1999;17(11):1075-81.

99

Toporovski R, Morrow MP and Weiner DB. Interferons as potential adjuvants in prophylactic
vaccines. Expert Opin Biol Ther 2010;10(10):1489-500.

28

100

Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V and Banchereau J. Plasmacytoid dendritic
cells induce plasma cell differentiation through type i interferon and interleukin 6. Immunity
2003;19(2):225-34.

101

Tovey MG, Lallemand C, Meritet JF and Maury C. Adjuvant activity of interferon alpha:
Mechanism(s) of action. Vaccine 2006;24 (Suppl 2):46-7.

102

Tovey MG and Maury C. Oromucosal interferon therapy: Marked antiviral and antitumor
activity. J Interferon Cytokine Res 1999;19(2):145-55.

103

Goldwater PN. Randomized comparative trial of interferon-alpha versus placebo in hepatitis b
vaccine non-responders and hyporesponders. Vaccine 1994;12(5):410-4.

29

Table 1: Commercially available interferon products

Product

Brand

FDA-approved indications

names
Interferon alfa-2a &

Roferon-A

Usual doses in adults for
treatment of indicated infections

Chronic HCV, hairy cell leukemia

3 million units SC three times

and AIDS-related Kaposi’s

weekly

sarcoma
PEG Interferon α-2a

Pegasys

Chronic HBV, HCV

injection
Interferon alfa-2b &

180 mcg SC q week x 24 or 48
weeks

Intron A

Chronic HBV, chronic HCV,

3 million units SC three times

condylomata acuminuta, hairy

weekly

cell leukemia, follicular
lymphoma, and AIDS-related
Kaposi’s sarcoma

PEG Interferon α-2b

PegIntron,

injection

Sylatron

Interferon alfacon

Infergen

Chronic HCV, melanoma

1.5 mcg/kg SC q week x 24 or 48
weeks

Chronic HCV

injection

15 mcg SC daily with ribavirin for
retreatment of IFN refractory
disease

Interferon alfa-n3

Alferon N

injection

Refractory or recurring external

Intralesional injection of 250,000

condylomata acuminata

IU (0.05 mL) per wart twice
weekly for up to 8 weeks.

Interferon beta-1a

Avonex,

Relapsing multiple sclerosis

Not indicated for infection

30

injection

Rebif

Interferon beta-1b

Betaseron

Relapsing multiple sclerosis

Not indicated for infection

ACTIMMUNE

Reduction in the frequency and

50 mcg/m2 (1 million IU/m2) for

severity of serious infections

patients whose BSA is greater

associated with CGD or

than 0.5m2 SC three times

treatment of severe, malignant

weekly

injection
Interferon gamma-1b
injection

osteopetrosis
Imiquimod 5% topical

Aldara

cream

Actinic keratoses of the face or

Apply topically three times per

scalp, superficial basal cell

week until total clearance of

carcinoma, external genital and

warts or a maximum of 16 weeks

perianal warts/condyloma
acuminata
Imiquimod 3.75%

Zyclara

cream

Actinic keratoses of the full face

Apply once daily to the warts

or balding scalp, external genital

until total clearance or up to 8

and perianal warts/condyloma

weeks.

acuminata
HBV = Hepatitis B Virus infection, HCV = Hepatitis C Virus Infection, SC = subcutaneously, q= every, AIDS
= Acquired Immunodeficiency Syndrome, CGD = chronic granulomatous disease, IU = international units,
BSA = body surface area
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